Implantable Device Biocompatibility Under ISO 10993

Start With the Actual Implant Exposure, Not a Generic Matrix

ISO 10993-1:2025 frames biological safety within risk management. For an implant, the evaluation should begin with the finished device, its anatomical location, the tissues or blood it contacts, exposure duration, patient population, materials, manufacture and foreseeable changes over use. The fact that a product is called an implant does not by itself establish the correct evidence strategy.

Duration is only one part of the contact model. FDA’s current endpoint tables distinguish limited contact (24 hours or less), prolonged contact (more than 24 hours to 30 days), and long-term or permanent contact (more than 30 days). They also distinguish implant contact with tissue or bone from implant contact with blood. An implant may have additional delivery-system components with a different contact type and duration, so the whole system sometimes needs more than one category.

The tables are a starting point, not a testing order. FDA says each recommended endpoint should be addressed through existing data, additional endpoint-specific testing, or a rationale for why further assessment is unnecessary. Novel materials, manufacturing processes, relevant target populations and intended degradation can introduce questions beyond the table.

Define the Finished-Device Boundary

FDA evaluates the whole device in its final finished form, including sterilization where applicable. Its biocompatibility assessment overview specifically points to materials, manufacturing methods, sterilization and residuals. For an implant, a credible configuration record normally covers:

• every direct and indirect patient-contacting component, including coatings, membranes, adhesives, markers and joining materials;
• surface finishing, cleaning, passivation, curing, printing, machining or other processes that can change the interface;
• sterilization method, validated processing range, packaging and the shelf-life state represented by the evidence;
• implant location, tissue or blood contact, cumulative exposure, intended residence and any repeat exposure from accessories;
• device-family variants and the rationale for which model or models represent each biological question.

This prevents evaluation of “titanium,” “PEEK” or “silicone” in the abstract. A familiar base material can still have different alloy composition, additives, surface topography, residues or coating integrity.

Representative Device Logic Is Endpoint-Specific

A single largest implant is not automatically the universal worst case. Representative selection should be documented against the hazard being evaluated. Useful comparison factors include material formulation, patient-contacting surface area, surface-area-to-mass relationship, geometry and inaccessible cleaning features, coating mass, manufacturing site and process, sterilization dose or residual challenge, duration and nature of contact, and the quantity or rate of constituent release.

Different family members can maximize chemical exposure, surface treatment, cleaning challenge or sterilization exposure. If different test articles cover different endpoints, use a coverage map rather than calling one model worst case for everything. FDA’s test-article comparison examples show relevant comparison factors.

Integrate Chemistry and Toxicology With Time

ISO 10993-18:2020, including Amendment 1:2022, provides a stepwise chemical-characterization framework, and ISO 10993-17:2023, including Amendment 1:2025, addresses toxicological risk assessment of device constituents. For implants, those activities should reflect realistic exposure rather than becoming stand-alone reports:

• Initial exposure: manufacturing residuals, sterilant residuals, unreacted monomers, processing aids or an early burst release can dominate soon after implantation.
• Steady-state exposure: diffusion, corrosion, hydrolysis, coating release or other mechanisms may produce a lower but prolonged exposure.
• Late or changing exposure: aging, wear, fatigue, coating delamination or material degradation can alter what is released and the tissue interface.

The toxicological assessment needs defensible patient-exposure assumptions, constituent identity and uncertainty, relevant duration, route and population. A favorable margin for one time window does not automatically resolve a different release phase, and chemical characterization does not replace the evaluation of physical hazards such as particulate debris or surface morphology.

Degradation Needs Its Own Decision Path

Degradation is relevant to both intentionally degradable implants and nominally permanent devices. ISO 10993-9:2019 provides a general framework for evaluating potential and observed degradation, including materials not intended to degrade. Material-specific parts address polymeric, ceramic, and metallic degradation products. The current ISO 10993-6:2026 addresses preclinical assessment of local effects after implantation when such evaluation is required.

Ask what can change chemically, physically and mechanically over the intended life. Metal corrosion, polymer hydrolysis and ceramic dissolution create different questions. Mechanical wear particles also require biological consideration even though purely mechanical degradation is outside the methods described by ISO 10993-9.

For absorbable devices, consider mass loss, molecular-weight change, fragmentation, local concentration, clearance and tissue response together. If accelerated studies are used, justify why acceleration does not create a clinically irrelevant pathway.

Long-Term Endpoint Logic Must Be Explicit

FDA’s long-term implant categories include a broad set of biological effects for consideration, with haemocompatibility added for blood-contacting implants. The quality check is not whether every effect has a new standalone animal study. It is whether every relevant biological question is traceably resolved using appropriate evidence or a justified rationale.

For example, implantation evidence should be tied to the relevant material state, anatomical context, duration and local tissue question. Genotoxicity, chronic toxicity and carcinogenicity reasoning may draw on chemistry and toxicology, but the chain from identified constituents and exposure to the conclusion must be visible. Reproductive or developmental toxicity needs focused consideration where novel materials, known hazards, the target population or local presence make it relevant. Blood-contacting implants need device-appropriate haemocompatibility reasoning rather than a generic statement that the base material has been used before.

A Lifecycle Decision Logic for Implant Changes

Use a structured reassessment whenever the implant, process or use changes:

1. Define the change: formulation, supplier, coating, geometry, surface finish, cleaning, manufacturing site, packaging, sterilization, shelf life, indication or contact profile.
2. Identify affected exposures and hazards: determine whether the change can alter chemistry, residuals, degradation, wear, surface interaction or representativeness of existing test articles.
3. Map existing evidence: identify which reports still represent the changed device and where the comparison depends on assumptions.
4. Resolve uncertainty proportionately: use controlled supplier information, comparative chemistry or physical characterization, toxicological assessment, focused biological testing, or another scientifically justified method as appropriate.
5. Update the connected file: revise the BEP or evaluation strategy, BER, risk-management records and any other affected technical documentation. Record future triggers so the conclusion has a defined boundary.

“No new testing” can be an outcome of this analysis, but it should not be the starting assumption. Under EU MDR, Annex I Section 10 of the consolidated Regulation (EU) 2017/745 expressly calls attention to material choice, tissue and body-fluid compatibility, compatibility between the different parts of a device that consists of more than one implantable part, the effects of processes on material properties, and mechanical properties such as wear and fatigue.

Hypothetical, Anonymized-Style Example: A Coated Bone-Screw Family

This fictionalized example uses no client data and is not a prescription for a real device. Consider sterile metallic bone screws in several lengths, with one optional surface coating. The longest screw may maximize surface area; the coating introduces a distinct formulation and interface; a smaller geometry may have a different surface-area-to-mass relationship. No member is worst case without a defined question.

A practical coverage map could select the configuration with maximum patient exposure for chemical assessment, separately address the coated interface and coating integrity, and verify that sterilization and manufacturing ranges are represented. Existing implantation or toxicology evidence would be compared against the current alloy, surface, process and contact duration. If the coating supplier later changes, the lifecycle analysis would revisit composition, impurities, application and curing, release and degradation, then identify which conclusions remain applicable. This example demonstrates the logic only; the required evidence depends on the real device and regulatory pathway.

What to Pressure-Test Before You Call the Implant File Ready

• Do the BEP and BER identify the current finished, sterilized and shelf-life-relevant configuration?
• Are tissue or bone, blood and delivery-system contacts categorized separately where needed?
• Is each representative device justified for the specific endpoint or exposure it supports?
• Are early, steady-state and late chemical or degradation exposures addressed where relevant?
• Do coatings, residues, wear particles and intended or unintended degradation enter the biological-risk analysis?
• Can every endpoint conclusion be traced to controlled evidence, limitations and the risk-management file?
• Are supplier, process, sterilization, packaging and shelf-life changes linked to documented reassessment triggers?